Markets:

Overview

News

Currencies

International

Treasuries

Abbott Laboratories (NY:ABT)

130.59 +1.33 (+1.03%)

Official Closing Price Updated: 7:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

50 51 Next >

Peering Into Abbott Laboratories's Recent Short Interest ↗

March 16, 2023

Via Benzinga

Healthcare Stocks With at Least 30 Years of Dividend Increases

March 14, 2023

Among the many industry sectors to invest in, healthcare can be one of the most stable, especially regarding the dividend yield.

Via MarketBeat

FDA Seeks 10% Increase In Biden's FY 2024 Budget, Proposes Enhancing Regulatory Authorities ↗

March 10, 2023

Via Benzinga

2 Top Dividend Stocks You Can Buy and Hold Forever ↗

March 09, 2023

These two companies have been growing their payouts for more than a century combined.

Via The Motley Fool

Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason ↗

March 07, 2023

Via Benzinga

2 Top Dividend Kings to Buy for the Long Haul ↗

March 04, 2023

These aren't just dividend plays, either.

Via The Motley Fool

Why The Apple Watch Comes Up Short In Heart Attack Detection… And Other Alternatives ↗

March 06, 2023

While there can be some value in having a single-lead ECG always available, patients with known heart conditions need much better technology.

Via Talk Markets

7 Dividend Kings to Buy for an Uncertain Market Environment ↗

March 06, 2023

With so much turbulence in the global economy, these dividend kings to buy may help you weather the extreme storm.

Via InvestorPlace

Healthcare Is Lagging But Biotech Offers Good Potential For Value And Trading ↗

March 06, 2023

Over the past week, the market had a nice uptick making it harder for defensive sectors like healthcare to get traction up only 0.51% and down almost 5% YTD.

Via Talk Markets

Dexcom Pummeled On A New FDA Clearance For Key Rival Abbott Laboratories ↗

March 06, 2023

The FDA will allow two of Abbott's CGMs to be paired with automated insulin pumps.

Via Investor's Business Daily

Abbott's MitraClip Shows Long Term Benefits In Patients With Leaky Heart Valves ↗

March 06, 2023

Via Benzinga

Data Shows Abbott's TriClip System Superior To Other Medical Therapy In Heart Valve Disorder ↗

March 06, 2023

Via Benzinga

2 High-Yield Dividend Stocks to Buy in March ↗

March 04, 2023

Putting some shares of these stocks in your portfolio now could lead to heaps of passive income in your retirement years.

Via The Motley Fool

ABBOTT LABORATORIES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Abbott Laboratories - ABT

March 03, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

1 High-Flying Growth Stock With 19% Upside, According to Wall Street ↗

March 03, 2023

This company could keep going up, but beware of the risks.

Via The Motley Fool

Dexcom Nears Breakout On A Surprise Medicare Decision For Its Devices ↗

March 02, 2023

The decision came months ahead of Dexcom's and Abbott's expectations.

Via Investor's Business Daily

Build Your Wealth by Buying and Holding These 2 Dividend Stocks for at Least 20 Years ↗

March 02, 2023

The road to wealth is long, but it'll be a bit shorter with the right investments.

Via The Motley Fool

Get a Dividend Every Month With These 3 Healthcare Stocks ↗

March 01, 2023

With a little planning, you can receive a dependable dividend payout every month.

Via The Motley Fool

Lucira Stock Jumps over 250% on FDA Approval, Beware Chapter 11

March 01, 2023

Lucira Health Inc. (NASDAQ: LHDX) shares spiked up 264% to close at $0.52 on a massive 278 million shares traded on the announcement of FDA approval for its

Via MarketBeat

Topics Initial Public Offering

Why Abbott Laboratories Stock Bumped Higher Today ↗

February 28, 2023

The company's specialized heart care products appear to prove their value in clinical testing.

Via The Motley Fool

How Is The Market Feeling About Abbott Laboratories? ↗

February 28, 2023

Abbott Laboratories's (NYSE:ABT) short percent of float has risen 11.43% since its last report. The company recently reported that it has 13.19 million shares sold short, which is 0.78% of all regular...

Via Benzinga

Should Abbott and DexCom Investors Be Worried About Apple's Latest News? ↗

February 28, 2023

The continuous glucose monitoring market could heat up.

Via The Motley Fool

Better Dividend Stock: Abbott Laboratories or Medtronic? ↗

February 27, 2023

One of these top dividend stocks is a far more compelling buy today.

Via The Motley Fool

Top 5 Health Care Stocks That May Rocket Higher In Q1 2023 ↗

February 27, 2023

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Via Benzinga

Better Buy: Abbott Laboratories or DexCom Stock? ↗

February 24, 2023

Both stocks should benefit from the growth in diabetes care.

Via The Motley Fool

Why Abbott Laboratories Stock Sank Today ↗

February 22, 2023

The company's glucose monitoring business might come under some serious pressure.

Via The Motley Fool

What Does Apple Have To Do With DexCom Stock Trading Lower? ↗

February 22, 2023

DexCom shares (NASDAQ: DXCM) are trading lower on Wednesday following a report that Apple Inc (NASDAQ: AAPL) is making progress on no-prick glucose tracking for its Watch.

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: NUVASIVE (Nasdaq – NUVA), Oak Street Health (NYSE – OSH), Argo Group International Holdings, Ltd. (NYSE - ARGO), Cardiovascular Systems, Inc. (Nasdaq – CSII)

February 22, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

3 Top Dividend Kings to Buy for the Long Haul ↗

February 20, 2023

These companies have more than 150 years of dividend growth between them.

Via The Motley Fool

2 Exceptional Growth Stocks Billionaires Keep Buying With Both Hands ↗

February 20, 2023

A poor performance from the broad market didn't stop these billionaire hedge fund managers from placing big bets on three supercharged growth stocks.

Via The Motley Fool

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

50 51 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Abbott Laboratories (NY:ABT)

All News about Abbott Laboratories

Starting at $3.75/week.

Subscribe Today